NPI 1669407847: Open Payments
NPI 1669407847. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$906 in 38 payments from 11 companies in 2025. Trend: 2023 $602 · 2024 $922 · 2025 $906
Food & beverage: $906
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 7 | $201 |
| Vanda Pharmaceuticals Inc. | 7 | $193 |
| Collegium Pharmaceutical, Inc. | 6 | $119 |
| Corium, LLC | 3 | $86 |
| ABBVIE INC. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Almatica Pharma LLC | 3 | $49 |
| Tris Pharma Inc | 2 | $47 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
Products named: Qelbree, HETLIOZ, Jornay PM, Azstarys, VRAYLAR, CAPLYTA, LOREEV XR, Dyanavel XR.
